The COVAX on Thursday said the recent surge in Covid-19 cases in India has severely impacted the Covid vaccine supply in the second quarter of this year. The COVAX is co-led by CEPI, Gavi and WHO, alongside key delivery partner UNICEF
In a joint statement, the COVAX said the supply affected to the extent that there will be a shortfall of 190 million doses by the end of June.
The joint statement was issued by Coalition for Epidemic Preparedness Innovations (CEPI) CEO Dr Richard Hatchett, Gavi, the Vaccine Alliance CEO Dr Seth Berkley, World Health Organization (WHO) Director-General Dr Tedros Adhanom Ghebreyesus and UNICEF Executive Director Henrietta Fore.
The joint statement said the countries that are advanced in their vaccination programmes are witnessing Covid decline, hospitalisations decrease and early signs of some kind of normality resume. However, the global picture is far more concerning.
Giving a call to deliver 2 billion Covid vaccine doses in 2021, the COVAX, in a statement said the COVAX is observing traumatic effects of the terrible surge of Covid-19 in South Asia – a surge which has also severely impacted global vaccine supplies.
The statement said COVAX has proven it works as the global mechanism for equitable access to Covod-19 vaccines, having delivered over 70 million doses to 126 countries and economies around the world since February. Over 35 countries received their first Covid-19 vaccine doses thanks to COVAX.
It said even though COVAX will have larger volumes available later in the year through the deals it has already secured with several manufacturers, it warned that India does not address the current, urgent shortfall, the consequences could be catastrophic. It said the pandemic has just taken a frightening new turn, as a deadly surge of cases rages across South Asia and other hotspots.
The global agencies called on nations to share doses now, saying the United States and Europe have collectively pledged to share 180 million doses.
The joint statement said COVAX’s need for doses is greatest right now. Countries with higher coverage rates, which are due to receive doses soon, should swap their places in supply queues with COVAX so that doses can be equitably distributed as quickly as possible.
The Serum Institute of India (SII), the world’s largest vaccine manufacturer, is the key supplier of AstraZeneca doses to COVAX.
As per the agreement between GAVI and SII to support an increase in manufacturing capacity through funding. The SII has contracted with COVAX to provide SII-licensed Covishield to 64 lower-income economies participating in the Gavi COVAX AMC (including India), alongside its commitments to the Government of India.
However, supply of vaccines from SII to COVAX has been impacted as the Covid second wave ravages India. UNICEF had also noted with concern that the devastating surge in coronavirus cases in India has impacted vaccine supplies to the COVAX facility.
A note to editors in the UNICEF statement had said that the shortfall numbers are based on delays related to shipments from the SII only. Other delays related to the original COVAX delivery schedule are expected to be made up by the end of June. The note said there is currently no timetable to resolve SII-related delays.
The COVAX facility is slated to deliver its 65 millionth dose in the coming days when it should have been at least its 170 millionth.
Read Also: Dominica Court stays Mehul Choksi’s deportation, grants legal aid
The COVAX is the only global initiative that is working with governments and manufacturers to ensure Covid-19 vaccines are available worldwide to both higher-income and lower-income countries.
According to Johns Hopkins University Covid-19 tracker, more than 168,769,000 confirmed cases have been reported from across the world while the deadly disease has claimed the lives of over 3,507,000 people.